$MARKSANS Marksans Pharma Ltd has posted a strong Q1 FY27 performance

$MARKSANS Marksans Pharma Ltd has posted a strong Q1 FY27 performance, driven by robust exports and steady domestic growth. The company’s consolidated revenue rose 22.4 % year‑on‑year to ₹ 706.5 crore, while net profit jumped 31.8 % to ₹ 118.2 crore. 💊 Q1 FY27 Financial Highlights Metric Q1 FY27 Q1 FY26 Growth YoY Revenue from Operations ₹ 706.5 crore ₹ 577.3 crore + 22.4 % EBITDA ₹ 157.8 crore ₹ 122.6 crore + 28.7 % EBITDA Margin 22.3 % 21.2 % + 1.1 pp PAT ₹ 118.2 crore ₹ 89.7 crore + 31.8 % EPS (Diluted) ₹ 2.85 ₹ 2.17 + 31.3 % Key drivers: Strong performance in regulated markets (US, UK, Australia). Growth in OTC and prescription segments. Operational efficiency from ABCnow GmbH acquisition and integration synergies. 🏭 Strategic Updates ABCnow GmbH integration completed; expected to add ₹ 250 crore annual revenue. New product launches in pain management and gastro segments. Capex plan of ₹ 150 crore for expansion of Goa and UK facilities. Focus on Europe and US growth through new ANDA filings and partnerships. 💹 Stock Performance (14 Aug 2026) Exchange Price Change Trend BSE ₹ 189.40 ▲ + 4.25 % Bullish short‑term NSE ₹ 188.85 ▲ + 4.10 % Positive momentum 52‑week range: ₹ 132.50 – ₹ 192.00 Technical outlook: Consolidation near ₹ 190 resistance; breakout could target ₹ 210 levels. ⚠️ Risks & Investor Watchpoints Regulatory compliance in EU and US markets. Currency fluctuations impacting export margins. Integration risks from recent acquisitions. In summary: Marksans Pharma Ltd continues its upward trajectory with strong export‑led growth and successful integration of ABCnow GmbH. The company’s focus on regulated markets and new product launches positions it well for sustained profitability.